CATX 最新10-Q变化

相对上期新增的文字 · 来源:10-Q · 2026-05-11

• We initially dosed two patients in Cohort 1 (treated at 2.5 mCi per dose) and seven patients in Cohort 2 (treated at 5.0 mCi per dose) of our Phase 1/2a clinical trial (NCT05636618) of [212Pb]VMT-α-NET in patients with unresectable or metastatic SSTR2-expressing NETs, regardless of body weight. Subs…

• In late June 2025, we announced the opening of Cohort 3 in which patients are receiving up to four fixed administered doses of [212Pb]VMT-α-NET at 6.0 mCi every eight weeks if they weigh more than 60 kg (133 lb), or 100μCi/kg of body weight if they weigh less than or equal to 60 kg. Eight Cohort 3 p…

• Cohort 4 is now open for recruitment. This cohort explores optimizing a 20 mCi cumulative dose by front-loading, with 6.0 mCi in the first dose, 5.0 mCi in the second dose, 5.0 mCi in the third dose, and 4.0 mCi in the fourth dose. The purpose of this dosing regimen is to determine whether front-loa…

• During the dose-finding phase of the study, we enrolled primarily NET patients whose disease originated in the pancreas or the digestive tract. We have an allowance for enrollment of NET patients whose disease originated in the lung (of which small cell lung cancer is a subset), pheochromocytoma and…

• We opened a proof-of-concept cohort of meningioma patients. To date, there is no approved systematic therapy for this disease. The unmet medical need may support an expedited development path.

相对上期删除的文字 · 来源:10-Q · 2025-11-10

• We initially dosed two patients in Cohort 1 (treated at 2.5 mCi per dose) and seven patients in Cohort 2 (treated at 5.0 mCi per dose) of our Phase 1/2a study of [212Pb]VMT-α-NET in patients with unresectable or metastatic SSTR2-expressing NETs, regardless of body weight. Subsequent review for dose-…

• During October 2025, updated interim results from our ongoing Phase 1/2a clinical trial (NCT05636618) of [212Pb]VMT-α-NET in patients with unresectable or metastatic SSTR2-expressing NETs with a data cut-off date of September 12, 2025, were presented at the European Society for Medical Oncology (ESM…

• In this analysis, 55 patients across three dose cohorts received at least one treatment of VMT-α-NET. Two patients in Cohort 1 and 23 patients in Cohort 2 had at least nine months of follow up since their initial treatment.

• Safety findings based on the 55 patients who received at least one treatment demonstrated that [212Pb]VMT-α-NET continued to be well tolerated. There were no DLTs, no treatment-related discontinuations, no grade 4 or 5 treatment-emergent AEs, no serious renal complications and no clinically signific…

• Anti-tumor activity based on all patients in Cohort 1 and half of the patients enrolled in Cohort 2 showed that out of these 25 patients, 20, or 80.0%, were progression free. Eight patients achieved confirmed responses according to investigator-assessed RECIST v1.1, all of which occurred in Cohort 2…

相对上期新增的文字 · 来源:10-Q · 2026-05-11

• Form of Pre-Funded Warrant, incorporated by reference to Exhibit 4.1 of the Form 8-K filed on February 3, 2026.

相对上期删除的文字 · 来源:10-Q · 2025-11-10

• Executive Employment Agreement, effective as of September 4, 2025, by and between Perspective Therapeutics, Inc. and Joel Sendek.

• Separation Agreement, effective September 24, 2025, between Perspective Therapeutics, Inc. and Juan Graham.